Disc Medicine, Inc. (NASDAQ:IRON) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Disc Medicine, Inc. (NASDAQ:IRON) have earned a consensus recommendation of “Moderate Buy” from the twelve research firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and ten have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $107.70.

A number of research analysts recently issued reports on the stock. Wedbush boosted their target price on shares of Disc Medicine from $88.00 to $100.00 and gave the company an “outperform” rating in a research report on Wednesday. Wall Street Zen lowered shares of Disc Medicine from a “hold” rating to a “sell” rating in a report on Saturday, August 29th. Cantor Fitzgerald restated an “overweight” rating on shares of Disc Medicine in a research note on Tuesday. HC Wainwright boosted their target price on Disc Medicine from $118.00 to $120.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $90.00 price target on shares of Disc Medicine in a research note on Monday, August 17th.

Insiders Place Their Bets

In related news, insider Rahul Khara sold 7,500 shares of Disc Medicine stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $70.22, for a total transaction of $526,650.00. Following the transaction, the insider owned 52,173 shares of the company’s stock, valued at $3,663,588.06. The trade was a 12.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Jonathan Yen-Wen Yu sold 18,612 shares of the stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $69.19, for a total value of $1,287,764.28. Following the completion of the sale, the chief operating officer directly owned 54,324 shares of the company’s stock, valued at $3,758,677.56. The trade was a 25.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 153,612 shares of company stock worth $11,431,811. Insiders own 3.76% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. California State Teachers Retirement System lifted its position in shares of Disc Medicine by 8,273.0% during the 2nd quarter. California State Teachers Retirement System now owns 2,878,790 shares of the company’s stock worth $210,555,000 after buying an additional 2,844,408 shares in the last quarter. BlackRock Inc. bought a new stake in Disc Medicine during the second quarter worth $180,502,000. RA Capital Management L.P. boosted its position in Disc Medicine by 25.3% in the fourth quarter. RA Capital Management L.P. now owns 1,976,132 shares of the company’s stock worth $156,925,000 after purchasing an additional 399,026 shares during the last quarter. Vanguard Group Inc. grew its stake in Disc Medicine by 22.1% in the 4th quarter. Vanguard Group Inc. now owns 1,767,680 shares of the company’s stock valued at $140,371,000 after purchasing an additional 319,621 shares during the period. Finally, Wellington Management Group LLP grew its stake in Disc Medicine by 0.3% in the 2nd quarter. Wellington Management Group LLP now owns 1,741,351 shares of the company’s stock valued at $127,362,000 after purchasing an additional 5,975 shares during the period. 83.70% of the stock is currently owned by hedge funds and other institutional investors.

Disc Medicine Stock Up 1.8%

Shares of NASDAQ IRON opened at $80.05 on Thursday. The company has a 50 day simple moving average of $77.49 and a 200 day simple moving average of $70.15. The company has a debt-to-equity ratio of 0.09, a current ratio of 24.14 and a quick ratio of 24.14. Disc Medicine has a 1 year low of $40.00 and a 1 year high of $99.50. The firm has a market cap of $3.07 billion, a PE ratio of -12.17 and a beta of 0.98.

Disc Medicine (NASDAQ:IRON) last announced its earnings results on Thursday, July 30th. The company reported ($1.54) EPS for the quarter, topping the consensus estimate of ($1.71) by $0.17. On average, research analysts forecast that Disc Medicine will post -6.61 EPS for the current year.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.